Please assess the completion status of the following clinical trial:

Trial Title: Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. 18 years of age or older~2. EF \< 40% via echocardiogram within the past 12 months~3. Stable dose of heart failure medications for \> past 1 month~4. NYHA class II - IV~Exclusion Criteria~1. Pregnant or lactating female~2. Receiving IV inotrope~3. History of significant non-compliance~4. Unwilling to adhere to the protocol~5. Systemic systolic BP less than 90 mmHg at screening visit~6. History of allergy to probenecid~7. History of gout~8. History of renal calculi~9. Recent unstable coronary artery syndromes (USA, admission to hospital for AMI, revascularization procedure, or acute decompensated HF requiring hospitalization) within the past 3 months.~10. Implant of CRT device within the past 3 months~11. TIA, CVA or major surgery within the past 3 months~12. Valvular heart disease (more than moderate stenosis or insufficiency)~13. HOCM, myocarditis, constrictive pericarditis, congenital heart disease, 14 Active chemotherapy, significant malignancy or uncontrolled metabolic disease (untreated hyper or hypothyroidism, Cushing's disease etc.)What about uncontrolled DM?? HgA1C \> etc~15. Elevated liver enzymes (\> 3 times ULN), 16. Current atrial fibrillation or frequent PVCs (should we define this now) 17. End stage renal disease (dialysis dependent) or worsening renal insufficiency should define now.~18. History of gastric ulcerations, significant gastroesophageal reflux. 19. Other condition that in the opinion of the investigator, would make the subject a poor candidate for the study.~20. Co-administration of any medication that in the opinion of the investigator places the subject at increased risks due to potential adverse drug interactions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Probenecid (Type: EXPERIMENTAL): Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
- placebo (Type: PLACEBO_COMPARATOR): Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).